Sareum Holdings Plc · LSE:SAR
Sareum — H1 2026 Earnings Presentation
21 slides from Sareum's earnings presentation, Mar 12, 2026
Slide 1: Unaudited Interim Results for the Six Months Ended 31 December 2025
Unaudited Interim Results for the Six Months Ended 31 December 2025 12 March, 2026 Dr Stephen Parker, Executive Chairman Dr Tim Mitchell, COO & Co-founder Dr John Reader, CSO & Co-founder
Slide 2: Disclaimer
DISCLAIMER The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have profession
Slide 3: Sareum: advancing next-generation therapies for autoimmune diseases and cancer
Sareum: advancing next-generation therapies for autoimmune diseases and cancer • Restarted the Phase 2-enabling toxicology programme for SDC-1801 with a leading global CRO; all subjects have commenced dosing. • The restart followed discontinuation of the previous 16-week GLP study after unexpected f
Slide 4: Progressing our pipeline - development
Progressing our pipeline - development Programme Discovery Preclinical Clinical Phase 1 Clinical Phase 2 Clinical Phase 3 Potential Indications Psoriasis, RA, Lupus, IBD TYK2 / JAK1 Autoimmune disease SDC-1801 – Phase 2 enabling toxicology programme underway Acute respiratory symptoms of viral infec
Slide 5: TYK2 / JAK1 inhibitor programmes
TYK2 / JAK1 inhibitor programmes Proprietary pipeline
Slide 6: Supportive commercial environment, validated science
Supportive commercial environment, validated science VALIDATED SCIENCE COMMERCIAL POTENTIAL BROAD POTENTIAL APPLICABILITY Approval of BMS’s TYK2 inhibitor Psoriasis affects > 125m Sotyktu (TYK2i) is approved for Sotyktu (deucravacitinib) without worldwide and had an approx. psoriasis and psoriatic a
Slide 7: SDC-1801: differentiated mechanism, strong safety profile
SDC-1801: differentiated mechanism, strong safety profile Programme Overview • SDC-1801 is a selective TYK2/JAK1 inhibitor being developed for autoimmune diseases, with an initial focus on psoriasis. • Positive data from the Phase 1 clinical trial, including single ascending dose (SAD) and multiple
Slide 8: How SDC-1801 stands apart from brepocitinib
How SDC-1801 stands apart from brepocitinib Brepocitinib SDC-1801 Blood cell effects Clinically relevant reductions in No clinically relevant changes in key blood cells observed at blood cell counts at equivalent higher doses (100mg/day) doses (140mg/day) Kidney function Increases in a kidney functi
Slide 9: Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies
Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies % Patients achieving PASI-75 reduction in psoriasis after 12 weeks (PASI-75 = 75% improvement in psoriasis symptoms – a common clinical goal) 30mg/day In clinical trials, brepocitinib (a TYK2/JAK1
Slide 10: SDC-1801 Has Potential for Best-in-Class Efficacy
SDC-1801 Has Potential for Best-in-Class Efficacy SDC-1801 has potential to achieve superior efficacy to biologic therapies • PASI 90 is the “gold standard” score for psoriasis patients • Biologics e.g. Skyrizi (IL-23 antibody): 18% achieve PASI 90 after 4 weeks, 75% after 16 %PASI 90 Achieved Acros
Slide 11: SDC-1802: Cancer immunotherapy
SDC-1802: Cancer immunotherapy Immunomodulating molecule that has demonstrated good efficacy in preclinical models of cancer • SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer and cancer immunotherapy applications. • Translational studies have been completed, providing a solid data packa
Slide 12: Expanding into CNS - targeting neuroinflammatory diseases
Expanding into CNS - targeting neuroinflammatory diseases Strong scientific rationale for Sareum's brain-penetrant Market opportunity TYK2/JAK1 inhibition in CNS compounds show promise Growing evidence that TYK2 A first batch of compounds has Neuroinflammatory diseases affect inhibition plays a key
Slide 13: AI-powered discovery acceleration
AI-powered discovery acceleration About Announced August 2025: Initial 4-month partnership to optimise brain- penetrant TYK2/JAK1 inhibitors. Approach Receptor.AI will support this work using virtual screening and PK predictive models, and Sareum will oversee compound synthesis, testing, ADMET profi
Slide 14: Chk1 – SRA737
Chk1 – SRA737 Selective Chk1 kinase inhibitor Once daily oral administration Completed Phase 1/2
Slide 15: Validated science with broad potential applicability
Validated science with broad potential applicability VALIDATED SCIENCE COMMERCIAL POTENTIAL BROAD POTENTIAL APPLICABILITY Chk1 forms part of the DNA No approved Chk1 inhibitors Clinical and preclinical studies Damage Response (DDR) creates a first-in-class support the use of a selective pathway, a w
Slide 16: SRA737: Clinical-stage oncology asset with enhanced value and partnering optionality
SRA737: Clinical-stage oncology asset with enhanced value and partnering optionality • SRA737 is a clinical-stage oral, selective inhibitor of checkpoint kinase 1 (Chk1), targeting cancer cell replication and DNA damage repair mechanisms. • Sareum holds the licence for SRA737 on significantly improv
Slide 17: Preliminary Financial Results
Preliminary Financial Results For the Six Months Ended 31 December 2025
Slide 18: Income statement
Income statement Financial results 6m ended 31 Year ended 30 6m ended 31 December 2025 June 2025 December 2024 (Unaudited) (Audited) (Unaudited) £’000 £’000 £’000 Revenue -) -) - Administrative expenses (1,820) (3,382) (1,346) Share of loss of associate - 2) (2) Operating loss (1,820) (3,380) (1,348
Slide 19: Balance sheet
Balance sheet Financial results: 31 December 2025 30 June 2025 31 December 2024 (Unaudited) (Audited) (Unaudited) £’000 £’000 £’000 Non-current assets Property, plant and equipment -) -) -) Investment in associate -) -) 7) -) 7) Current assets Trade and other receivables 747 684) 553) Cash and cash
Slide 20: Pipeline status and priorities
Pipeline status and priorities SDC-1801 • The dosing phase of the Phase 2-enabling toxicology programme is expected to complete in mid-2026, with the full regulatory package anticipated by year-end. • Strong Phase 1 data and positive read-across across the TYK2/JAK1 field reinforce confidence in SDC
Slide 21: Sareum Holdings plc
Sareum Holdings plc Unit 2A, Langford Arch London Road, Pampisford Cambridge CB22 3FX United Kingdom Tel: +44 (0) 1223 497700 Email: info@sareum.com 21